Green Ribbon Co., Ltd. (CEO Kim Gyu-ri), a data-driven bio-fintech company, announced on the 13th that it participated in 'BIO JAPAN 2025' held in Yokohama, Japan from October 8th and introduced its AI-based clinical trial subject prediction platform 'GreenScout'.
Green Ribbon participated in the exhibition through the Ministry of SMEs and Startups' "K-STARTUP BIO" joint pavilion, introducing AI patient screening technology and a clinical trial subject prediction model based on actual cost insurance and clinical trial data. During the exhibition, Green Ribbon held collaborative discussions with major Japanese pharmaceutical companies and global contract research organizations (CROs), particularly focusing on potential collaboration in the fields of regenerative medicine and rare diseases.
Green Scout is an AI solution that automatically identifies candidate patients who meet the inclusion and exclusion criteria for clinical trial protocols, leveraging the real-world data (RWD) of approximately 2.5 million domestic users. It integrates and analyzes various variables, including diagnostic history, medication patterns, and visit frequency, to provide hospitals and pharmaceutical companies with a "recruitment probability prediction report" based on a 0-100 score.
Green Ribbon explained that the technology can shorten the time required to recruit clinical trial subjects from an average of 1-2 years to about 2 months, and has secured cases where the screening failure rate was reduced from over 50% to less than 20%.
Kim Gyu-ri, CEO of Green Ribbon, said, “Green Scout is a platform that can increase the speed and efficiency of clinical trials based on actual medical data,” and added, “We will expand our cooperation to contribute to the global clinical trial market by utilizing Korea’s medical data-based AI technology.”
- See more related articles
You must be logged in to post a comment.